Seth A. Kareus, MD; Karla P. Figueroa, MS; Lisa A. Cannon-Albright, PhD; et al.
free access
Arch Neurol. 2012;69(12):1572-1577. doi:10.1001/archneurol.2012.2261
Kareus and colleagues used a computerized genealogy for Utah pioneers and their descendants linked to a statewide cancer registry and death certificates to estimate relative risks for cancer in individuals with Parkinson disease listed on their death certificate and among their first-degree, second-degree, and third-degree relatives. Walter A. Rocca, MD, MPH, provides an accompanying editorial.
-
Editorial
Families With Parkinson Disease and Cancer
Walter A. Rocca, MD, MPH
Arch Neurol
Ross W. Paterson, MRCP; Charles C. Torres-Chae, MPA; Amy L. Kuo, MS, RN, GNP; et al.
free access
Arch Neurol. 2012;69(12):1578-1582. doi:10.1001/2013.jamaneurol.79
In a retrospective medical record review, Paterson et al identify the misdiagnoses of patients with sporadic Jakob-Creutzfeldt disease during the course of disease and determine which medical specialties saw these patients prior to the correct diagnosis being made and at what point in the disease course a correct diagnosis was made. See the related editorial by Caselli.
Zhengrui Xi, PhD; Lorne Zinman, MD; Yakov Grinberg, PhD; et al.
free access
Arch Neurol. 2012;69(12):1583-1590. doi:10.1001/archneurol.2012.2016
Using a 2-step genotyping strategy, Xi et al estimate the allele frequency of C9orf72 (G4C2) repeats in amyotrophic lateral sclerosis, frontotemporal lobar degeneration, Alzheimer disease, and Parkinson disease.
Yafei Huang, PhD; Rachel Potter, BA; Wendy Sigurdson, MSN; et al.
free access
Arch Neurol. 2012;69(12):1591-1597. doi:10.1001/archneurol.2012.18107
In a repeated plasma and cerebrospinal fluid sampling study, Huang et al investigate dynamic changes in human plasma 尾-amyloid concentrations, evaluate the effects of aging and amyloidosis on these dynamics, and determine their correlation with cerebrospinal fluid 尾-amyloid concentrations.
James P. Klaas, MD; J. Eric Ahlskog, PhD, MD; Sean J. Pittock, MD; et al.
free access
has multimedia
Arch Neurol. 2012;69(12):1598-1607. doi:10.1001/archneurol.2012.1173
Klaas et al evaluate 21 adults with opsoclonus-myoclonus syndrome (OMS) and review the literature to contribute to the sparse data available on adult-onset OMS.
-
Video:
Adult-Onset Opsoclonus-Myoclonus Syndrome
Peter J. Dyck, MD; Carol J. Overland; Phillip A. Low, MD; et al.
free access
Arch Neurol. 2012;69(12):1609-1614. doi:10.1001/archneurol.2012.1481
After a previous trial resulted in inaccurate assessment of diabetic sensorimotor polyneuropathy, Dyck et al used more specific diagnostic criteria and compared findings with nerve conduction studies.
Raymond C. S. Seet, MD; Eelco F. M. Wijdicks, MD, PhD; Alejandro A. Rabinstein, MD
free access
Arch Neurol. 2012;69(12):1615-1620. doi:10.1001/archneurol.2012.2569
To describe the outcomes of intravenous thrombolysis or endovascular treatment in patients with stroke from acute cervical internal carotid artery occlusion, Seet and colleagues performed among 21 patients a retrospective study of the associations of vascular predictor variables with favorable functional recovery at 90 days after stroke.
Adam M. Brickman, PhD; Frank A. Provenzano, BS; Jordan Muraskin, BS; et al.
free access
Arch Neurol. 2012;69(12):1621-1627. doi:10.1001/archneurol.2012.1527
In a longitudinal community-based epidemiological study of older adults from northern Manhattan, New York, Brickman et al determine whether regional white matter hyperintensities and hippocampal volume predict incident Alzheimer disease.
Vikas Kotagal, MD; Nicolaas I. Bohnen, MD, PhD; Martijn L. T. M. Müller, PhD; et al.
free access
Arch Neurol. 2012;69(12):1628-1631. doi:10.1001/archneurol.2012.764
Kotagal et al determine whether serotoninergic system degeneration in Parkinson disease (PD) promotes 尾-amyloid deposition, using in vivo positron emission tomographic probes of serotonin system integrity and 尾-amyloid deposition.
Ihab Hajjar, MD, MS; Lauren Brown, BS, MPH; Wendy J. Mack, PhD; et al.
free access
Arch Neurol. 2012;69(12):1632-1638. doi:10.1001/archneurol.2012.1010
Hajjar and colleagues evaluate the impact of treatment with angiotensin receptor blockers (ARBs) on the neuropathology of Alzheimer disease (AD) in the National Alzheimer Coordinating Center database, which includes aggregated data and brain autopsies from 29 AD centers throughout the United States.